Clinical trials: Limited Stage
Breast Cancer
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer
This study is looking at whether Metformin, an agent that is commonly used to treat diabetes, can decrease or affect the ability of breast cancer cells to grow and whether Metformin will work with other therapies to keep cancer…
- Trial name
- NCT01101438
- Testing
- metformin hydrochloride
- Where
- 344 sites in United States, Canada and 2 more
- Volunteers
- 3,649 people
- Sponsor
- Canadian Cancer Trials Group
Early Stage Breast Cancer
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
The purpose of this study is to see whether taking denosumab for 12 months in women with a significant number of disseminated tumor cells in the bone marrow can reduce the number of these cells below a significant level.
- Trial name
- NCT01545648
- Testing
- Denosumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Hope Rugo, MD
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7
The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer
The purpose of this pilot phase II trial is to identify the molecular and genetic mechanisms by which statins influence breast cancer cell proliferation.
- Conditions
- Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
- Trial name
- NCT03454529
- Testing
- Laboratory Biomarker Analysis, Simvastatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Michael Simon
Stage I Uterine Sarcoma AJCC v7, Uterine Corpus Leiomyosarcoma
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
This randomized phase III trial studies how well gemcitabine hydrochloride and docetaxel followed by doxorubicin hydrochloride work compared to observation in treating patients with high-risk uterine leiomyosarcoma previously…
- Trial name
- NCT01533207
- Testing
- Clinical Observation, Docetaxel, Doxorubicin Hydrochloride
- Where
- 623 sites in United States, Belgium and 6 more
- Volunteers
- 38 people
- Sponsor
- Gynecologic Oncology Group
Breast Cancer
Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse
Women with breast cancer who are not eligible for breast conserving surgery or who have node-involvement are sometimes treated with chemotherapy up front, in hopes of allowing for a woman to keep her breast and decreasing the…
- Trial name
- NCT00462865
- Testing
- Gemcitabine and Capecitabine and Avastin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Brown University
Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma
Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy
This pilot clinical trial studies caloric restriction in patients with stage 0-I breast cancer during surgery and radiation therapy. Reducing caloric intake may prevent disease progression in patients with breast cancer.
- Conditions
- Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Lobular Breast Carcinoma in Situ
- Trial name
- CAREFOR (NCT01819233)
- Testing
- Behavioral dietary intervention, Therapeutic conventional surgery, Radiation therapy
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Breast Cancer, Hormone Changes
Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as triptorelin, may protect normal ovarian cells from the side effects of…
- Conditions
- Breast Cancer, Hormone Changes, Drug Toxicity
- Trial name
- NCT00090844
- Testing
- triptorelin
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of South Florida
Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
This randomized phase III trial is studying cisplatin, radiation therapy, and tirapazamine to see how well they work compared to cisplatin and radiation therapy in treating patients with cervical cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer
- Trial name
- NCT00262821
- Testing
- cisplatin, tirapazamine
- Where
- 282 sites in United States, Canada
- Volunteers
- 402 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of Head of Pancreas
Neoadjuvant Folfirinox Followed by Capecitabine and Limited Field Radiation for Localized Pancreatic Head Adenocarcinoma
This study is for subjects with adenocarcinoma of the pancreas. The purpose of this research study is to determine the safety and effectiveness of modified Folfirinox and radiation therapy as treatment for adenocarcinoma (cancer)…
- Trial name
- NCT01677988
- Testing
- Neo-adjuvant Chemotherapy, Chemoradiation, Surgical Resection
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Medical University of South Carolina
Breast Cancer
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
The goal of this clinical research study is to learn if and how well eribulin, given in combination with standard chemotherapy, can treat early-stage breast cancer compared to paclitaxel given in combination with standard…
- Trial name
- NCT01593020
- Testing
- Paclitaxel, Eribulin, 5-Fluorouracil
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Parkinson's Disease
A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation
Primary Objectives: Part 1: To determine the safety and tolerability of 4, 8, and 15 milligrams of GZ/SAR402671 (venglustat) administered orally for 4 weeks, as compared to placebo in participants with early-stage Parkinson's…
- Trial name
- MOVES-PD (NCT02906020)
- Testing
- venglustat GZ/SAR402671
- Where
- 52 sites in United States, Austria and 14 more
- Volunteers
- 273 people
- Sponsor
- Genzyme, a Sanofi Company
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
This phase II trial studies how well hypofractionated radiation therapy works in treating patients with stage 0-IIB breast cancer.
- Conditions
- Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer, Stage I Breast Cancer
- Trial name
- NOVEMBER (NCT03345420)
- Testing
- Hypofractionated Radiation Therapy
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Utah
Lung Cancer, Non Small Cell Lung Carcinoma
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
The trial investigates the feasibility and efficacy of targeting Non-Small Cell Lung Cancer (NSCLC) "driven" by epigenetic changes.
- Conditions
- Lung Cancer, Non Small Cell Lung Carcinoma, Hypermethylation
- Trial name
- NCT01209520
- Testing
- Cisplatin, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Miami
Breast Cancer
Evaluating Whether Integration of Prognostic and Predictive Algorithms Into Routine Clinical Practice Effect Whether Oncologists Order Multigene Assays in Patients With Early Stage Breast Cancer
A broad range of prognostic and predictive tools are available for patients with newly diagnosed early stage breast cancer. These range from free and publicly available mathematical algorithms, through to expensive genomic tests.
- Trial name
- REaCT-Algorith (NCT04131933)
- Where
- 6 sites in Canada
- Volunteers
- 602 people
- Sponsor
- Ottawa Hospital Research Institute
Cervical Cancer
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00980954
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 125 sites in United States, Canada and 2 more
- Volunteers
- 236 people
- Sponsor
- Radiation Therapy Oncology Group
Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
The purpose of the study is to determine whether tolvaptan is effective and safe for the treatment of late-stage chronic kidney disease due to autosomal dominant polycystic kidney disease (ADPKD)
- Trial name
- NCT02160145
- Testing
- Tolvaptan (OPC-41061)
- Where
- 230 sites in United States, Argentina and 20 more
- Volunteers
- 1,370 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Early-Stage Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease.
- Trial name
- SP512OL (NCT00594165)
- Testing
- Rotigotine
- Where
- 42 sites in United States, Canada
- Volunteers
- 217 people
- Sponsor
- UCB Pharma
Neoplasms, Malignant Solid Tumors
Cancer Vaccine Targeting Brachyury Protein in Tumors
Background: Cancer vaccines are being developed to help teach the body's immune system to attack and destroy cancer cells. A new vaccine being tested targets Brachyury protein.
- Conditions
- Neoplasms, Malignant Solid Tumors, Colon Neoplasms, Adenocarcinoma
- Trial name
- NCT01519817
- Testing
- GI-6301 (Yeast Brachyury Vaccine)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Overweight or Obesity
Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study
This is a single arm phase II study designed to determine the effects of pharmacotherapy and a remote behavioral weight loss intervention on weight loss in breast cancer survivors who are overweight or obese, and the impact of…
- Trial name
- A-NEW (NCT04499950)
- Testing
- Contrave, Behavioral Weight Loss
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
This phase II trial evaluates how well AVD (doxorubicin, vinblastine, dacarbazine) in combination with brentuximab vedotin and nivolumab work in treating patients with stage I-II Hodgkin lymphoma.
- Conditions
- Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma
- Trial name
- NCT03233347
- Testing
- Brentuximab Vedotin, Dacarbazine, Doxorubicin
- Where
- 9 sites in United States
- Volunteers
- 83 people
- Sponsor
- Academic and Community Cancer Research United